Observational studyBritish journal of haematology2026
Immune-related adverse events in the treatment of Hodgkin lymphoma with immune checkpoint inhibitors.
Observational study in British journal of haematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Sarcoid-like Reactions in Hodgkin Lymphoma Treated with Pembrolizumab.Mediterranean journal of hematology and infectious diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Immune checkpoint inhibitors (ICIs) have shown to be effective in the treatment of Hodgkin lymphoma (HL). ICI treatment is associated with the occurrence of a series of immune-related adverse events (irAEs). We conducted an ambispective observational study on 96 patients with relapsed/refractory HL treated with ICIs to determine the incidence of irAEs, their type, severity and their correlation with treatment outcomes. Fifty patients were treated with pembrolizumab (52.1%) and 46 patients were treated with nivolumab (47.9%). A total of 22 patients (22.9%) developed at least one irAE, resulting in a total of 27 irAEs. The results of our study did not show statistically significant differences between the two cohorts of patients, suggesting that the presence of these peculiar toxicities does not significantly impact outcomes and survivals in patients with HL treated with ICIs. However, the complexity of irAEs, their classification as such and the variability in response to immunotherapy require further studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.